Bleeding and ischaemic events after first bleed in anticoagulated atrial fibrillation patients: risk and timing

Pascal B Meyre, Steffen Blum, Elisa Hennings, Stefanie Aeschbacher, Tobias Reichlin, Nicolas Rodondi, Jürg H Beer, Annina Stauber, Andreas Müller, Tim Sinnecker, Elisavet Moutzouri, Rebecca E Paladini, Giorgio Moschovitis, Giulio Conte, Angelo Auricchio, Alexandra Ramadani, Matthias Schwenkglenks, Leo H Bonati, Michael Kühne, Stefan OsswaldDavid Conen

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


AIMS: To determine the risk of subsequent adverse clinical outcomes in anticoagulated patients with atrial fibrillation (AF) who experienced a new bleeding event.

METHODS AND RESULTS: Anticoagulated AF patients were followed in two prospective cohort studies. Information on incident bleeding was systematically collected during yearly follow-up visits and events were adjudicated as major bleeding or clinically relevant non-major bleeding (CRNMB) according to the International Society on Thrombosis and Haemostasis guidelines. The primary outcome was a composite of stroke, myocardial infarction (MI), or all-cause death. Time-updated multivariable Cox proportional-hazards models were used to compare outcomes in patients with and without incident bleeding. Median follow-up was 4.08 years [interquartile range (IQR): 2.93-5.98]. Of the 3277 patients included (mean age 72 years, 28.5% women), 646 (19.7%) developed a new bleeding, 297 (9.1%) a major bleeding and 418 (12.8%) a CRNMB. The incidence of the primary outcome was 7.08 and 4.04 per 100 patient-years in patients with and without any bleeding [adjusted hazard ratio (aHR): 1.36, 95% confidence interval (CI): 1.16-1.61; P < 0.001; median time between a new bleeding and a primary outcome 306 days (IQR: 23-832)]. Recurrent bleeding occurred in 126 patients [incidence, 8.65 per 100 patient-years (95% CI: 7.26-10.30)]. In patients with and without a major bleeding, the incidence of the primary outcome was 11.00 and 4.06 per 100 patient-years [aHR: 2.04, 95% CI: 1.69-2.46; P < 0.001; median time to a primary outcome 142 days (IQR: 9-518)], and 59 had recurrent bleeding [11.61 per 100 patient-years (95% CI: 8.99-14.98)]. The incidence of the primary outcome was 5.29 and 4.55 in patients with and without CRNMB [aHR: 0.94, 95% CI: 0.76-1.15; P = 0.53; median time to a composite outcome 505 days (IQR: 153-1079)], and 87 had recurrent bleeding [8.43 per 100 patient-years (95% CI: 6.83-10.40)]. Patients who had their oral anticoagulation (OAC) discontinued after their first bleeding episode had a higher incidence of the primary composite than those who continued OAC (63/89 vs. 159/557 patients; aHR: 4.46, 95% CI: 3.16-6.31; P < 0.001).

CONCLUSION: In anticoagulated AF patients, major bleeding but not CRNMB was associated with a high risk of adverse outcomes, part of which may be explained by OAC discontinuation. Most events occurred late after the bleeding episode, emphasizing the importance of long-term follow-up in these patients.

Original languageEnglish
Pages (from-to)4899-4908
Number of pages10
JournalEuropean Heart Journal
Issue number47
Early online date26 Oct 2022
Publication statusPublished - 14 Dec 2022


  • Atrial fibrillation
  • bleeding
  • death
  • oral anticoagulation
  • outcomes
  • stroke


Dive into the research topics of 'Bleeding and ischaemic events after first bleed in anticoagulated atrial fibrillation patients: risk and timing'. Together they form a unique fingerprint.

Cite this